Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large b-cell lymphoma: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 10, 2015, Pages 17515-17522

  Meng, Fanlu ^a   Zhong, Diansheng ^a   Zhang, Linlin ^a   Shao, Yi ^a   Ma, Qing ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

CHOP; Diffuse large B cell lymphoma; Meta analysis; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; META ANALYSIS; MIDDLE AGED; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84949664147     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pasqualucci L and Dalla-Favera R. SnapShot: Diffuse Large B Cell Lymphoma. Cancer Cell 2014; 25: 132.
2. Staudt LM and Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005; 87: 163-208.
3. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001; 13: 325-334.
4. Gatter K and Pezzella F. Diffuse large B-cell lymphoma. Diagnostic Histopathology 2010; 16: 69-81.
5. Jones SE, Grozea PN, Miller TP, Van Slyck EJ, Balcerzak SP, Costanzi JJ, Morrison FS, Eyre HJ, Fabian CJ and Dabich L. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study. J Clin Oncol 1985; 3: 1318-1324.
6. Plosker GL and Figgitt DP. Rituximab. Drugs 2003; 63: 803-843.
7. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932.
8. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H and Morschhauser F. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005; 23: 4117-4126.
9. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A and Hagenbeek A. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999; 17: 1244-1244.
10. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-253.
11. Avilés A, Nambo MJ, Neri N, Cleto S, Castañeda C, Huerta-Guzmàn J, Murillo E, Contreras M, Talavera A and González M. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+ R) in high-risk diffuse large cell lymphoma. Med Oncol 2007; 24: 85-89.
12. Avilés A, Nambo MJ, Castañeda C, Cleto S, Neri N, Murillo E, Huerta-Guzmán J and Contreras M. Rituximab and escalated chemotherapy in elderly patients with aggressive diffuse large-cell lymphoma: a controlled clinical trial. Can-cer Biother Radiopharm 2007; 22: 194-199.
13. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009; 2009: 523-531.
14. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA and Cabanillas F. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
15. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haïoun C, Foussard C and Sebban C. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101-106.
16. Ivano V, Coso D, Chetaille B, Esterni B, Olive D, Aurran-Schleinitz T, Schiano JM, Stoppa AM, Broussais-Guillaumot F and Blaise D. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55: 1-6.
17. Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, El-Mehidi N, John-son PW and Radford J. De Novo Treatment of Diffuse Large B-Cell Lymphoma With Rituxi-mab, Cyclophosphamide, Vincristine, Gemci-tabine, and Prednisolone in Patients With Cardiac Comorbidity: A United Kingdom Nat-ional Cancer Research Institute Trial. J Clin Oncol 2014; 32: 282-287.
18. Pfreundschuh M, Kuhnt E, Trümper L, Öster-borg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R and Jaeger U. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12: 1013-1022.
19. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M and Sebban C. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010; 116: 2040-2045.
20. Peter N, Hutter G, Zimmermann Y, Hiddemann W and Dreyling M. Rituximab But Not GA101 Is Partially Antagonistic With Inhibitors Of The B-Cell Receptor Pathway In Diffuse Large B-Cell Lymphoma. Blood 2013; 122: 4420-4420.
21. Koivula S, Valo E, Raunio A, Hautaniemi S and Leppä S. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma. Oncol Rep 2011; 25: 1183-1190.
22. Fu Z, Zhu J, Zheng W, Liu W, Ying Z, Xie Y, Wang X, Lin N, Tu M and Ping L. Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma. Cancer Cell Int 2014; 14: 5.
23. Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, LaCasce A, Morrison J, Elstrom R and Ely S. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 690-697.
24. Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G and Morschhauser F. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858-1867.
25. Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T and Récher C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol 2013; 24: 1032-1037.
26. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N and Reed V. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010; 28: 4170-4176.
27. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M and Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87: 146-171.
28. Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA and McMillan A. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013; 381: 1817-1826.
29. Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M and Fruchart C. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013; 14: 525-533.